spirogermanium has been researched along with aclacinomycin in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asbury, RF; Cnaan, A; Haller, DG; Harris, J; Johnson, L; Zaentz, SD | 1 |
1 trial(s) available for spirogermanium and aclacinomycin
| Article | Year |
|---|---|
An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Topics: Aclarubicin; Adenocarcinoma; Adjuvants, Immunologic; Antineoplastic Agents; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Pancreatic Neoplasms; Spiro Compounds; Survival Rate | 1994 |